Inspira Technologies OXY B.H.N. Ltd. announced the company?s next major milestone of a core blood oxygenation technology of the INSPIRA ART (Gen 2). The INSPIRA ART (Gen 2) is designed to utilize adaptive oxygenation technology, leveraging the proprietary HYLA? blood Sensor and VORTX?

Orbiting Blood Oxygenation, to delivery oxygen straight into the blood. The proprietary core technology has undergone a series of testing in a variety of settings, with the results being collected and analyzed. The results refer to the INSPIRA ART (Gen 2), with the new core technology potentially being suitable for replacing current solutions in medical markets dominated by leading medical device companies.

The Company plans to announce the primary results around the core blood oxygenation technology of the INSPIRA ART (Gen 2) within days. Emphasizing the Company?s core mission, Mr. Hayon continued to share how Inspira is focused on delivering oxygen straight into the blood. The Company is advancing two generations of blood oxygenation solutions.

INSPIRA ART100 (Gen 1), designed to perform blood oxygenation as a cardio-pulmonary bypass device, is anticipated to be cleared by the FDA in the first half of 2024. With the planned FDA submission and clearance of the HYLA, the INSPIRA ART100 is then intended to be integrated with blood monitoring technologies from the HYLA. In parallel, the Company is rapidly developing the INSPIRA ART (Gen 2), designed to perform adaptive blood oxygenation, embedded with the HYLA advanced continuous blood monitoring, to provide real-time detection of changes and provide decision-making assistance data and the VORTX orbiting blood oxygenation delivery system.